All News

Some patient advocacy groups opposing Medicare changes have received funding from pharma companies in the past; new techniques allow scientists to target individual cells for analysis; rural nursing homes continue to close.

Low-value care that offers no benefit to patients, or can actually cause more harm than good, is costly to patients and the healthcare system. While low-value services are being identified and measured, it has been more difficult to reduce the use of low-value care.

According to recently published research, vitamins B12 and B9 can lower levels of homocysteine, improve anemia status, and boost physical health in patients with relapsing remitting multiple sclerosis (MS).

A recent study measured exhaled breath condensate (EBC) content that contained ultrafine particles (UFP) as a reflection of inflammation and oxidative stress in patients with chronic obstructive pulmonary disease (COPD) and as a marker of exacerbations.

In a recent study, researchers looked to analyze the association of migraine that presents with visual aura with atrial fibrillation (AF) as migraines with a visual aura are associated with a cardioembolic stroke risk.

A technology update, a new drug approval, and a drug recall due to more impurities.

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion that an orphan drug, volanesorsen (Waylivra), receive a conditional marketing authorization. The drug would be the first medication approved for the treatment of the familial chylomicronemia syndrome (FCS).

Organizations and agencies marked Rare Disease Day this week. Here are 5 things to know about rare disease.

Short-term investments pertaining to the distribution of PrEP are expected to result in long-term cost-savings and promote significant health benefits following its introduction in Germany, according to a new modelling study.

Since carfilzomib was approved at a 27 mg/m2 twice-weekly dose, it has since been optimized at 56 mg/m2 twice-weekly and a recent study found benefits of a 70 mg/m2 once-weekly dose. However, most patients are still treated with the original approval dosage, suggesting they might be undertreated.

This week, the top managed care news included pharmaceutical executives appearing before a Senate drug pricing hearing; HHS finalizing a Title X rule change; and an analysis that found travel and wait times for healthcare services come with a high price.

Scientists at the National Institutes of Health have recently found that biologic age, or a DNA-based estimate of a person’s age, is associated with future development of breast cancer.

Nearly 10% of drug approvals in 2018 were generic products for branded drugs that had no FDA-approved generics.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

Senator Bill Cassidy, R-Louisiana, is working with Democratic colleagues Michael Bennet of Colorado and Maggie Hassan of New Hampshire to introduce a bill this month to stop patients from getting surprise medical bills; the FDA warned a major Canadian drug distributor, CanaRx to stop selling unapproved and mislabeled medicines to Americans looking to save money on prescriptions; Democratic leaders in the House of Representatives are trying to keep the chamber united behind narrower proposals aimed at strengthening the Affordable Care Act and lowering drug prices in the wake of the introduction of a Medicare for All bill.

The vast majority of patients with COPD require greater motivation to seek help when symptom changes occur and are unaware of their increased risk of developing lung cancer, according to new research.

AstraZeneca and Merck will present full results at a future meeting; Myriad Genetics will file a supplemental application for its companion diagnostic.

How to improve patient-reported measurement in oncology valued-based care is the focus of a new report from The National Pharmaceutical Council and Discern Health.

Here are 5 interesting findings from the February 2019 issue of AJMC®.

Between 2014 and 2017, antivirals were consistently the number 1 most costly outpatient drug group for Medicaid, and HIV antiretrovirals and hepatitis C drugs accounted for more than 90% of spending on these antivirals.

A webinar presented by the Patient-Centered Primary Care Collaborative emphasized the issues that women continue to face regarding fairness and equality in modern healthcare, discussing topics such as caregiving, maternal and mental health, racial disparities, and more.

A new study determines the smallest change in upper extremity function that patients with multiple sclerosis (MS) find important or meaningful through an analysis in the change of scores of the Arm Functiom in Multiple Sclerosis Questionnaire.

Researchers have confirmed that there is no link between flu shots and miscarriages; a liquid biopsy is as effective as tissue-based testing for identifying treatment for lung cancer; and physicians generate an average of $2 million a year for hospitals.

Here are the top 5 articles for the month of February.

During the hearing on drug pricing held yesterday before the US Senate Committee on Finance, 7 pharmaceutical executives gave testimony in an effort to explain rising drug costs in the United States and offer solutions to lower them.

According to a new study, migraine is associated with a higher risk of open-angle glaucoma compared with patients with no migraine.

House Democrats are expected to introduce a Medicare for All bill today; CMS' Center for Medicare and Medicaid Innovation is planning to unveil a new payment model for primary care physicians; and CMS, CDC, and FDA have established a task force to improve future responses to public health emergencies.

Areas such as physical health showed improvement, but career and social well-being continue to weaken for Americans.